General practitioners (GPs) play a key role in early melanoma detection.
Publications
Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
In fifteen patients with stage 0–III melanoma, the numbers of CTCs were analyzed.
Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma
In this retrospective multicenter cohort study involving 387 patients, median (range) age 63 (17-88) years and 235 (60.7%) were male, with stage III to IV melanomas, researchers determined the incidence, time course, spectrum, and associations of chronic immune-related adverse events (irAEs) arising from adjuvant anti-programmed cell death 1 (anti–PD-1) therapy.
NCDB Analysis of Melanoma 2004-2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval
The incidence of invasive melanoma is rising, and approval for the first immune checkpoint inhibitor (ICI) to treat metastatic melanoma occurred in 2011.